Liposomal doxorubicin coated with polyethylene glycol data

SEQU (formerly Liposome Technology Inc., Menlo Park, Calif.) said that two dose-ranging, Phase I trials of the agent in a total of 56 patients

Read the full 245 word article

How to gain access

Continue reading with a
two-week free trial.